Consultant receives options for 7.4% stake in PMGC Holdings
ELAB is trading near its 52-week low of $1.62 (12% above the low) on light trading volume (0.1× avg).
Summary
A consultant to PMGC Holdings Inc. received options for 450,277 shares, increasing their beneficial ownership to 7.40% of the company.
Key Events · Ownership and Investor Activity · ELAB
-
Significant Option Grant
Braeden Lichti, through Northstrive Companies Inc., was granted options for 450,277 shares of common stock on June 1, 2026.
-
Purpose of Grant
The options were issued as partial consideration for consultant services provided to PMGC Holdings Inc.
-
Increased Beneficial Ownership
Following the grant, Braeden Lichti and Northstrive Companies Inc. now beneficially own 450,313 shares, representing 7.40% of the company's outstanding common stock on a post-reverse split basis.
-
Context of Dilution
This substantial equity grant adds to the company's recent pattern of significant share issuances and dilution, occurring amidst a 'going concern' warning and active capital raising efforts.
Analysis · ELAB · Life Sciences
This amendment to a Schedule 13D reveals that Braeden Lichti, through his wholly-owned entity Northstrive Companies Inc., was granted options for 450,277 shares on June 1, 2026. These options were partial consideration for consultant services. This grant significantly increases the beneficial ownership of the reporting persons to 7.40% of the company's outstanding shares. For a company with a recent 'going concern' warning and a history of substantial dilutive financing, such a large equity grant, representing a significant portion of the company's market value, is a material event that adds to the ongoing dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELAB was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $1.62 to $309.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.